Literature DB >> 17483069

Leukemogenesis of the EVI1/MEL1 gene family.

Kazuhiro Morishita1.   

Abstract

Leukemia is a group of monoclonal diseases that arise from hematopoietic stem and progenitor cells in the bone marrow or other hematopoietic organs. Retroviral infections are one of the major events leading to leukemogenesis in mice, because retroviruses can induce hematopoietic disease via the insertional mutagenesis of oncogenes; therefore, the cloning of viral-integration sites in murine leukemia has provided valuable molecular tags for oncogene discovery. Transcription of the murine gene ecotropic viral-integration site 1 (Evi1) is activated by nearby viral integration. In humans, the Evi1 homologue EVI1 is activated by chromosomal translocations. This review discusses the roles of the overexpression of EVI1/MEL1 gene family members in leukemogenesis, the relationships of various translocations in EVI1 overexpression, and the importance of PR domains in tumor suppression and oncogenesis. The functions of EVI1/MEL1 members as transcription factors and the concept of EVI1-positive leukemia as a stem cell disease are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483069     DOI: 10.1532/IJH97.06174

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  78 in total

1.  Differential gene expression profiling of adult murine hematopoietic stem cells.

Authors:  In-Kyung Park; Yaqin He; Fangming Lin; Ole D Laerum; Qiang Tian; Roger Bumgarner; Christopher A Klug; Kaijun Li; Christian Kuhr; Michelle J Doyle; Tao Xie; Michèl Schummer; Yu Sun; Adam Goldsmith; Michael F Clarke; Irving L Weissman; Leroy Hood; Linheng Li
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

2.  Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells.

Authors:  Mika Yoshida; Kisato Nosaka; Jun-ichirou Yasunaga; Ichiro Nishikata; Kazuhiro Morishita; Masao Matsuoka
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

3.  Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein.

Authors:  A S Perkins; R Fishel; N A Jenkins; N G Copeland
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

Review 4.  Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes.

Authors:  K Ohyashiki; J H Ohyashiki; T Shimamoto; K Toyama
Journal:  Leuk Lymphoma       Date:  1996-11

5.  Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).

Authors:  Ikuya Sakai; Tatsushiro Tamura; Hirosi Narumi; Naoyuki Uchida; Yoshihiro Yakushijin; Takaaki Hato; Shigeru Fujita; Masaki Yasukawa
Journal:  Genes Chromosomes Cancer       Date:  2005-11       Impact factor: 5.006

6.  EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation.

Authors:  Seiichi Shimizu; Toshiro Nagasawa; Osamu Katoh; Norio Komatsu; Jun Yokota; Kazuhiro Morishita
Journal:  Biochem Biophys Res Commun       Date:  2002-04-05       Impact factor: 3.575

Review 7.  EVI1 and hematopoietic disorders: history and perspectives.

Authors:  Giuseppina Nucifora; Leopoldo Laricchia-Robbio; Vitalyi Senyuk
Journal:  Gene       Date:  2005-11-28       Impact factor: 3.688

8.  Activation of EVI1 transcripts with chromosomal translocation joining the TCRVbeta locus and the EVI1 gene in human acute undifferentiated leukemia cell line (Kasumi-3) with a complex translocation of der(3)t(3;7;8).

Authors:  K Suzukawa; T Kodera; S Shimizu; T Nagasawa; H Asou; N Kamada; M Taniwaki; J Yokota; K Morishita
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

9.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

10.  Expression of EVI1 and the Retinoblastoma genes in acute myelogenous leukemia with t(3;13)(q26;q13-14).

Authors:  Y Yufu; S Sadamura; H Ishikura; Y Abe; M Katsuno; J Nishimura; H Nawata
Journal:  Am J Hematol       Date:  1996-09       Impact factor: 10.047

View more
  19 in total

1.  Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; José Cervera; Xabier Agirre; Oskar Marin-Béjar; Nerea Marcotegui; Carmen Vicente; Idoya Lahortiga; Maria Gomez-Benito; Claudia Carranza; Ana Valencia; Salut Brunet; Eva Lumbreras; Felipe Prosper; María T Gómez-Casares; Jesús M Hernández-Rivas; María J Calasanz; Miguel A Sanz; Jorge Sierra; María D Odero
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

2.  Enhanced expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells.

Authors:  Minenori Eguchi-Ishimae; Mariko Eguchi; Kazuma Ohyashiki; Tetsuya Yamagata; Kinuko Mitani
Journal:  Int J Hematol       Date:  2009-02-26       Impact factor: 2.490

3.  The subtype-specific features of EVI1 and PRDM16 in acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Susumu Goyama; Yasuhiko Kamikubo; Souichi Adachi
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

4.  Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.

Authors:  Ryutaro Kotaki; Hiroshi Higuchi; Daisuke Ogiya; Yasuhiro Katahira; Natsumi Kurosaki; Naoko Yukihira; Jun Ogata; Haruna Yamamoto; Syakira Mohamad Alba; Azran Azhim; Tatsuo Kitajima; Shigeaki Inoue; Kazuhiro Morishita; Koh Ono; Ryo Koyama-Nasu; Ai Kotani
Journal:  Int J Hematol       Date:  2017-08-22       Impact factor: 2.490

5.  PRDM16 Suppresses MLL1r Leukemia via Intrinsic Histone Methyltransferase Activity.

Authors:  Bo Zhou; Jingya Wang; Shirley Y Lee; Jie Xiong; Natarajan Bhanu; Qi Guo; Peilin Ma; Yuqing Sun; Rajesh C Rao; Benjamin A Garcia; Jay L Hess; Yali Dou
Journal:  Mol Cell       Date:  2016-04-14       Impact factor: 17.970

6.  PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature.

Authors:  David J Corrigan; Larry L Luchsinger; Mariana Justino de Almeida; Linda J Williams; Alexandros Strikoudis; Hans-Willem Snoeck
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

7.  An MLL-dependent network sustains hematopoiesis.

Authors:  Erika L Artinger; Bibhu P Mishra; Kristin M Zaffuto; Bin E Li; Elaine K Y Chung; Adrian W Moore; Yufei Chen; Chao Cheng; Patricia Ernst
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-06       Impact factor: 11.205

Review 8.  Integrating physiological regulation with stem cell and tissue homeostasis.

Authors:  Daisuke Nakada; Boaz P Levi; Sean J Morrison
Journal:  Neuron       Date:  2011-05-26       Impact factor: 17.173

9.  Prdm16 promotes stem cell maintenance in multiple tissues, partly by regulating oxidative stress.

Authors:  Sergei Chuikov; Boaz P Levi; Michael L Smith; Sean J Morrison
Journal:  Nat Cell Biol       Date:  2010-09-12       Impact factor: 28.824

10.  The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.

Authors:  Norio Yamakawa; Kazuko Kaneda; Yusuke Saito; Emi Ichihara; Kazuhiro Morishita
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.